Evaluate Pharma recently issued an article listing "the most valuable potential drugs currently under development", and Aficamten is one of them. Aficamten is a novel cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy, which achieves its therapeutic effect by reducing the hypercontractility of obstructive HCM and improving diastolic function.